
|Peer-Reviewed|December 24, 2020
- February 2021
- Volume 27
- Issue 2
Supplemental Material: Cost of Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer
Home administration of oral paclitaxel and encequidar is associated with potential cost savings for payers compared with clinic administration of intravenous chemotherapy in metastatic breast cancer patients.
Advertisement
Articles in this issue
over 4 years ago
Radiation Oncology’s Role in the Next Chapter of Payment Reformover 4 years ago
Flying the Plane While You Build Itover 4 years ago
The Untapped Potential of Cell and Gene Therapyover 4 years ago
Possible Treatment Identified for Aggressive NSCLC SubsetNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices
2
FDA Approves Lumateperone as Add-On Therapy for Major Depressive Disorder
3
CMS Announces GENEROUS Model to Lower Medicaid Drug Prices
4
Preventing Tomorrow’s High-Cost Claims: The Rising-Risk Patient Opportunity in Medicaid
5















































